The tumor distribution of ADCs depends on many factors, includingthe dose itself, systemic clearance rate, antigen expression level, endocytosis rate, and the tumor’s surface area to volume ratio (S/V). Poor tissue permeability remains a major challenge for antibody treatments of solid tumors, and appropriately increasing the dosage can improve the drug’s tissue distribution and enhance … Read more
IntroductionIn the field of breast cancer treatment, antibody-drug conjugates (ADC) are gradually becoming an important therapeutic approach.ADC drugs are a new type of cancer treatment that combines the targeting capability of antibodies with the potent killing power of chemotherapy drugs, allowing for precise delivery of chemotherapy agents to cancer cells, thereby improving efficacy and reducing … Read more
ADC drugs utilize monoclonal antibodies to specifically deliver cytotoxic drugs to tumor cells, characterized by precise targeting and specific killing of tumors, thereby limiting the exposure of cytotoxic drugs to normal cells or tissues. The main clinical toxicities of ADC drugs include gastrointestinal, hematological, hepatic, neurological, and ocular toxicities, which are usually dose-limiting[2]. Depending on … Read more
Antibody-drug conjugates (ADC) are a new class of targeted drugs composed of monoclonal antibodies (mAbs), cytotoxic drugs, and linkers that connect the two. They utilize the targeting capability of antibodies to selectively deliver cytotoxic molecules to tumor cells, exerting anti-cancer effects while avoiding impacts on healthy cells. ADC drugs have rapidly developed in the field … Read more
* For reference by medical professionals only What Issues Should Be Addressed During the Infusion of ADC Drugs for Breast Cancer? ADC drugs combine the precise targeting of antibody drugs with the efficient killing advantage of cytotoxic drugs, gradually changing the treatment landscape for breast cancer. Currently, ADC drugs that have entered clinical practice in … Read more
As early as 1913, during the 17th International Medical Congress, Professor Paul Ehrlich proposed the concept of the “magic bullet”, using monoclonal antibodies to specifically deliver cytotoxic drugs to tumor cells, thereby achieving the goal of killing tumor cells. With the development of monoclonal antibody production technology and the exploration of antibody conjugates, antibody-drug conjugates … Read more